$506.1 M

MGTA Mkt cap, 05-Dec-2019
Magenta Therapeutics Net income (Q3, 2019)-21 M
Magenta Therapeutics EBIT (Q3, 2019)-22.6 M
Magenta Therapeutics Cash, 30-Sept-201985.5 M

Magenta Therapeutics Income Statement

Annual

USDFY, 2018

R&D expense

41.3m

General and administrative expense

18.6m

Operating expense total

60.0m

EBIT

(60.0m)

Interest expense

2.4m

Interest income

2.4m

Net Income

(57.5m)

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

R&D expense

9.7m11.4m10.5m13.4m16.5m

General and administrative expense

4.3m5.3m5.8m5.9m6.1m

Operating expense total

14.0m16.7m16.4m19.3m22.6m

EBIT

(14.0m)(16.7m)(16.3m)(19.3m)(22.6m)

Interest income

365.0k687.0k1.5m1.6m1.7m

Income tax expense

Net Income

(13.7m)(16.0m)(14.8m)(17.7m)(21.0m)

Magenta Therapeutics Balance Sheet

Annual

USDFY, 2018

Cash

58.3m

Prepaid Expenses

2.8m

Current Assets

145.3m

PP&E

10.2m

Total Assets

157.3m

Accounts Payable

3.5m

Current Liabilities

10.4m

Non-Current Liabilities

1.2m

Total Liabilities

11.7m

Common Stock

33.0k

Additional Paid-in Capital

248.3m

Retained Earnings

(102.7m)

Total Equity

145.6m

Financial Leverage

1.1 x

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

173.4m159.7m31.2m33.1m85.5m

Prepaid Expenses

2.3m3.0m7.8m10.7m4.7m

Current Assets

175.9m162.9m135.1m183.0m165.2m

PP&E

2.9m8.1m10.6m10.6m10.2m

Total Assets

180.6m172.8m147.7m195.4m177.2m

Accounts Payable

1.5m4.9m3.0m2.3m2.0m

Current Liabilities

7.6m11.9m7.9m9.9m9.6m

Non-Current Liabilities

796.0k1.1m

Total Liabilities

8.4m13.0m13.7m15.9m15.7m

Common Stock

33.0k33.0k34.0k39.0k39.0k

Additional Paid-in Capital

242.2m245.8m251.5m314.6m317.7m

Retained Earnings

(70.0m)(86.0m)(117.6m)(135.3m)(156.3m)

Total Equity

172.2m159.8m134.0m179.6m161.5m

Financial Leverage

1 x1.1 x1.1 x1.1 x1.1 x

Magenta Therapeutics Cash Flow

Annual

USDFY, 2018

Net Income

(57.5m)

Depreciation and Amortization

875.0k

Accounts Payable

2.5m

Cash From Operating Activities

(41.9m)

Purchases of PP&E

(7.7m)

Cash From Investing Activities

(91.7m)

Cash From Financing Activities

142.1m

Net Change in Cash

8.6m

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(24.8m)(40.8m)(14.8m)(32.5m)(53.5m)

Depreciation and Amortization

307.0k516.0k423.0k875.0k1.4m

Accounts Payable

995.0k2.1m(658.0k)(430.0k)(629.0k)

Cash From Operating Activities

(18.7m)(29.3m)(14.9m)(30.0m)(41.5m)

Purchases of PP&E

(846.0k)(3.3m)(1.3m)(2.4m)(2.9m)

Cash From Investing Activities

(2.6m)(5.1m)(12.7m)(56.6m)7.3m

Cash From Financing Activities

143.4m142.6m563.0k61.3m61.4m

Net Change in Cash

122.0m108.3m(27.1m)(25.2m)27.2m

Magenta Therapeutics Ratios

USDY, 2019

Financial Leverage

1.1 x